Takeda's PhII meza­gi­ta­m­ab da­ta; Apogee's $483M raise; Gal­der­ma's IPO

Plus, news about Cy­bin, Mer­ck, Almi­rall, Eloxx Phar­ma­ceu­ti­cals and BioVie:

Take­da drug passed Phase II test: The pro­gram, meza­gi­ta­m­ab (TAK-079), is be­ing test­ed in per­sis­tent or chron­ic pri­ma­ry im­mune throm­bo­cy­tope­nia (ITP). An in­ter­im analy­sis showed pos­i­tive safe­ty and ef­fi­ca­cy re­sults, per a press re­lease, though ex­act da­ta fig­ures were not dis­closed. — Max Gel­man

Apogee clos­es $483 mil­lion of­fer­ing: The raise, up from an ini­tial­ly es­ti­mat­ed $350 mil­lion, comes a week af­ter Apogee’s atopic der­mati­tis treat­ment im­pressed Wall Street in a Phase I healthy vol­un­teer study — shares are up 100% since the start of March. — Max Gel­man

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.